December 26, 2011
SymBio Pharmaceuticals LimitedFuminori Yoshida
Representative Director
President and Chief Executive Officer

SymBio Initiates Japan Phase 2 Trial of Bendamustine HCl (SyB L-0501)
in Multiple Myeloma
TOKYO, Japan, December 26, 2011 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, President &CEO: Fuminori Yoshida, “SymBio”) announced that it has achieved first patient enrollment and started aphase 2 clinical trial on December 26 for bendamustine hydrochloride (SyB L-0501) in refractory and relapsed
multiple myeloma1 (MM) patients in Japan.

The number of multiple myeloma patients in Japan is estimated to be around 13,000, with an equal number ofrefractory/relapsed and frontline patients. Regarding SyB L-0501 development in MM, SymBio plans toprioritize development in refractory/relapsed MM patients who were previously treated with other oncology
drugs due to the high unmet medical need.
In Japan, SymBio received marketing approval of TREAKISYM® (SyB L-0501) in October, 2010, for thetreatment of patients with refractory/relapsed low-grade non-Hodgkin’s lymphoma 2 (NHL) and mantle celllymphoma (MCL). Working with Eisai Co. Ltd., TREAKISYM® is expected to achieve rapid market penetrationin Japan.

SymBio has also initiated phase 2 trials for SyB L-0501 in refractory/relapsed intermediate and high-grade
non-Hodgkin’s lymphoma patients. The Company continues to pursue other indications for TREAKISYM® inthe hematology space as nimbly as possible in order to maximize the potential of this ‘pipeline within amolecule’ and address other unmet medical needs in patients.

SymBio’s financial forecast for FY 2011 will not be revised due to the acceptance of clinical trial notification.

[Please read the following to learn more about multiple myeloma, non-Hodgkin’s lymphoma,
bendamustine hydrochloride (SyB L-0501), and SymBio Pharmaceuticals][Contact]

Hiroki Maekawa
Board Director, Corporate Officer, Chief Financial Officer
Tel: +081(0)3 5472 1125

Note to Editors

Glossary
1 Multiple Myeloma: is a hematological cancer in which there is the malignant proliferation of abnormal plasma cells that
populate the marrow-containing bones of the body.

The affected plasma cells produce myeloma protein, a monoclonal

antibody that replaces normal antibodies in the blood, thereby increasing susceptibility to infection and renal failure.
Symptoms include pain, anemia, weakness, bone fractures, and neurological symptoms. This is considered to be a
progressive and incurable disease; the number of multiple myeloma patients in Japan is estimated to be around 13,000,

with an equal number of refractory/relapsed and frontline patients
2 Non-Hodgkin’s Lymphoma: is a diverse group of blood cancers that include any kind of lymphoma, except Hodgkin'slymphomas, in which B or T white blood cells (lymphocytes) develop malignant growths - the majority of Japanesepatients suffer from non-Hodgkin's lymphomas. The disease is categorized by progression and has been divided into
low-grade (slow-growing) and intermediate to high-grade (fast-growing) types.

About Bendamustine Hydrochloride (SyB L-0501)
Bendamustine was first synthesized in the early 1960s in former ‘East Germany’ by Jenapharm, and iscurrently marketed in Germany under the brand name “Ribomustin®” as a treatment for non-Hodgkin’slymphoma, multiple myeloma and chronic lymphocytic leukemia. Mundipharma has received market
authorization in a number of EU countries for bendamustine under the brand name “Levact®.” In the UnitedStates, the drug has been approved by the U.S. Food and Drug Administration and is marketed asTREANDA® for the treatment of chronic lymphocytic leukemia and relapsed indolent B-cell non-Hodgkin'slymphoma. SymBio Pharmaceuticals Limited originally acquired the exclusive right from Astellas DeutschlandGmbH (Headquarters: Munich, Germany, formerly Astellas Pharma GmbH) to develop and commercialize
bendamustine in Japan (December, 2005), followed by signature of a second license agreement for theexclusive right to China/Hong Kong, Taiwan, South Korea and Singapore (March, 2007).
About TREAKISYM®
Product Name:
TREAKISYM® for Injection, for intravenous infusion 100 mg
Generic Name:bendamustine hydrochloride
Indications and Usage:
For the treatment of relapsed or refractory forms of the following indications:・ Low-grade B-cell non-Hodgkin’s lymphoma
・ Mantle cell lymphoma
Dosage and Administration:
The standard adult dose of bendamustine hydrochloride is 120 mg/m2 infused intravenouslyover 60 minutes on Days 1 and 2 of repeated 21-day cycles. The dose may be reduced as
deemed appropriate according to the patient’s condition.
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Ltd. was established in March, 2005, by Fuminori Yoshida, who previously served
concurrently as Corporate VP of Amgen Ltd. and founding President of Amgen Japan (currently Takeda Bio
Development Center Limited). The company’s underlying corporate mission is “delivering hope to patients inneed” as it aspires to be a leading specialty pharmaceutical company in Asia Pacific dedicated to addressing
underserved medical needs in the areas of oncology, hematology and autoimmune disease.